Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia
Lab on a Chip · 2025
DOI: 10.1039/d5lc00264h ↗Kurz gefasst
Fachartikel in der Zeitschrift Lab on a Chip, 2025. Verfasst von Zoe Sekyonda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Erythrocytes, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: FIC NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
This study establishes the chemically induced hypoxia OcclusionChip assay as a reliable clinical tool for evaluating red blood cell deformability in sickle cell disease, with potential to improve personalized treatment strategies and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
- Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, USA. umut@case.edu.
- Department of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, OH, USA.
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
ORCID-Profile: Zoe Sekyonda, Yuxuan Du, Solomon Oshabaheebwa, Payam Fadaei, Calvin Abonga, Michael A Suster, Pedram Mohseni, Umut A Gurkan
Förderung
- FIC NIH HHS
- NHLBI NIH HHS
- NIDDK NIH HHS
- Small Business Innovation Research
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- American Society of Hematology
- Fogarty International Center
Zitieren
APA
Sekyonda, Z., Du, Y., Oshabaheebwa, S., Fadaei, P., Ley, Y. B., Abonga, C., Suster, M. A., Mohseni, P., & Gurkan, U. A. (2025). Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia. Lab on a Chip. https://doi.org/10.1039/d5lc00264h
Vancouver
Sekyonda Z, Du Y, Oshabaheebwa S, Fadaei P, Ley YB, Abonga C, et al. Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia. Lab on a Chip. 2025. doi:10.1039/d5lc00264h
BibTeX
@article{Sekyonda2025,
author = {Sekyonda, Zoe and Du, Yuxuan and Oshabaheebwa, Solomon and Fadaei, Payam and Ley, Yusang B and Abonga, Calvin and Suster, Michael A and Mohseni, Pedram and Gurkan, Umut A},
title = {Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia},
journal = {Lab on a Chip},
year = {2025},
doi = {10.1039/d5lc00264h}
}
EUVIMED